Hitachi Chemical inks Daiichi Sankyo regenerative meds deal

By Flora Southey contact

- Last updated on GMT

GettyImages/Ankabala
GettyImages/Ankabala
Daiichi Sankyo has selected CDMO Hitachi Chemical Therapeutics Solutions to make regenerative medicine for the Japanese market.

Under the clinical manufacturing agreement, Hitachi Chemical will make Daiichi Sankyo’s investigative product at its facility in Yokohama City, Kanagawa Prefecture.

The site houses Hitachi Chemical’s PCT regenerative cell-focused service platform, which its off-shoot Hitachi Chemical Co. America purchased​ from majority shareholder Caladrius Biosciences last year.

Regenerative medicine describes the process of transplanting in-vitro ​cells into patients to help restore organ or immune functions affected by disease. Regenerative approaches include immunotherapy and somatic stem cell therapies, engineered immune cell therapy and induced pluripotent stem cells (iPSC).

Daiichi Sankyo spokesperson Koji Ogiwara did not disclose which investigational drug will be manufactured by Hitachi Chemical, nor did he provide details on the manufacturing timeframe.

In October last year, Hitachi Chemical announced plans​ to add 49,700 sq. ft. to its PCT service site in Allendale, New Jersey, US.

The firm also announced plans to upgrade its Pearl Court site in Allendale, and confirmed its regenerative cell-focused CDMO site in Yokohama would be validated by April this year.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers